secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023500
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614
--------------------------------------------------------------------------------

- Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.
- Net loss $1.7M in Q2 2025 vs $2.0M loss in Q2 2024; R&D expenses rose to $1.9M from $0.9M.
- Federal grant revenue $1.4M in Q2 2025 vs $0.2M in Q2 2024, driven by MPAR study activity.
- Initiated pivotal Phase 3 trial (PF614-301) for post-surgical pain; Rho, Inc. engaged as CRO.
- Received $5.3M NIDA installment and U.S. patent allowance for OUD candidate PF9001.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/0001641172-25-023500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer